Medibio (ASX: MEB) (OTC: MDBIF) CEO Interview with David Kaysen. Mr. Kaysen recently came on board as the new CEO, in this interview he discusses Medibio’s mental health monitoring technologies, ongoing progress towards full-scale commercializing, and his background in running small-cap med-tech companies. Kaysen sees 2019 as a “very important year for Medibio” with commercialization rollout, capital raising and FDA regulatory approvals.
Pluristem Therapeutics, Inc. (NASDAQ: PSTI), interview with co-CEO Yaky Yanay. Yaky explains Pluristem’s regenerative medicine technologies, which use placenta-derived cell products, and address multi-billion health markets. Pluristem has 3 […]
ISFIYA, Israel, May 04, 2018 — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW, CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, […]
BLA update and major licensing initiatives in cancer and immunology VANCOUVER, Washington, Jan 08, 2019- CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
